Corcept Therapeutics Inc (CORT)

$23.15

-0.36

(-1.53%)▲

Market is closed - opens 7 PM, 16 Apr 2024

Insights on Corcept Therapeutics Inc

  • Increasing Revenue

    Revenue is up for the last 6 quarters, 101.72M → 135.40M (in $), with an average increase of 5.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 31.37M → 31.35M (in $), with an average decrease of 0.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 47.0% return, outperforming this stock by 42.6%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 243.4% return, outperforming this stock by 241.7%

Performance

  • $22.92
    $23.63
    $23.15
    downward going graph

    0.99%

    Downside

    Day's Volatility :3.0%

    Upside

    2.03%

    downward going graph
  • $20.87
    $34.28
    $23.15
    downward going graph

    9.85%

    Downside

    52 Weeks Volatility :39.12%

    Upside

    32.47%

    downward going graph

Returns

PeriodCorcept Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-5.93%
-0.8%
0.0%
6 Months
-17.59%
5.7%
0.0%
1 Year
3.07%
3.0%
-0.7%
3 Years
1.69%
14.1%
-21.8%

Highlights

Market Capitalization
2.4B
Book Value
$4.9
Earnings Per Share (EPS)
0.94
PE Ratio
25.01
PEG Ratio
0.61
Wall Street Target Price
42.8
Profit Margin
22.0%
Operating Margin TTM
23.39%
Return On Assets TTM
11.13%
Return On Equity TTM
21.05%
Revenue TTM
482.4M
Revenue Per Share TTM
4.66
Quarterly Revenue Growth YOY
31.4%
Gross Profit TTM
396.5M
EBITDA
108.3M
Diluted Eps TTM
0.94
Quarterly Earnings Growth YOY
1.0
EPS Estimate Current Year
1.09
EPS Estimate Next Year
1.38
EPS Estimate Current Quarter
0.26
EPS Estimate Next Quarter
0.21

Analyst Recommendation

Buy
    75%Buy
    25%Hold
    0
    0%Sell
Based on 12 Wall street analysts offering stock ratings for Corcept Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 12 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
3
3
3
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 84.88%

Current $23.15
Target $42.80

Company Financials

FY18Y/Y Change
Revenue
251.2M
↑ 57.82%
Net Income
75.4M
↓ 41.6%
Net Profit Margin
30.01%
↓ 51.1%
FY19Y/Y Change
Revenue
306.5M
↑ 21.99%
Net Income
94.2M
↑ 24.89%
Net Profit Margin
30.73%
↑ 0.72%
FY20Y/Y Change
Revenue
353.9M
↑ 15.46%
Net Income
106.0M
↑ 12.56%
Net Profit Margin
29.96%
↓ 0.77%
FY21Y/Y Change
Revenue
366.0M
↑ 3.42%
Net Income
112.5M
↑ 6.13%
Net Profit Margin
30.74%
↑ 0.78%
FY22Y/Y Change
Revenue
401.9M
↑ 9.8%
Net Income
101.4M
↓ 9.86%
Net Profit Margin
25.24%
↓ 5.5%
FY23Y/Y Change
Revenue
482.4M
↑ 20.04%
Net Income
106.1M
↑ 4.66%
Net Profit Margin
22.0%
↓ 3.24%
Q3 FY22Q/Q Change
Revenue
101.7M
↓ 1.6%
Net Income
34.6M
↑ 26.25%
Net Profit Margin
34.02%
↑ 7.51%
Q4 FY22Q/Q Change
Revenue
103.1M
↑ 1.31%
Net Income
16.6M
↓ 52.03%
Net Profit Margin
16.11%
↓ 17.91%
Q1 FY23Q/Q Change
Revenue
105.7M
↑ 2.52%
Net Income
15.9M
↓ 4.35%
Net Profit Margin
15.03%
↓ 1.08%
Q2 FY23Q/Q Change
Revenue
117.7M
↑ 11.42%
Net Income
27.5M
↑ 73.36%
Net Profit Margin
23.39%
↑ 8.36%
Q3 FY23Q/Q Change
Revenue
123.6M
↑ 5.0%
Net Income
31.4M
↑ 13.99%
Net Profit Margin
25.39%
↑ 2.0%
Q4 FY23Q/Q Change
Revenue
135.4M
↑ 9.55%
Net Income
31.4M
↓ 0.07%
Net Profit Margin
23.16%
↓ 2.23%
FY18Y/Y Change
Total Assets
311.7M
↑ 41.33%
Total Liabilities
35.8M
↑ 21.11%
FY19Y/Y Change
Total Assets
412.3M
↑ 32.28%
Total Liabilities
41.1M
↑ 14.85%
FY20Y/Y Change
Total Assets
571.7M
↑ 38.66%
Total Liabilities
48.4M
↑ 17.66%
FY21Y/Y Change
Total Assets
423.8M
↓ 25.88%
Total Liabilities
48.0M
↓ 0.92%
FY22Y/Y Change
Total Assets
583.4M
↑ 37.68%
Total Liabilities
81.6M
↑ 70.15%
FY23Y/Y Change
Total Assets
621.5M
↑ 6.53%
Total Liabilities
114.8M
↑ 40.72%
Q3 FY22Q/Q Change
Total Assets
533.3M
↑ 7.43%
Total Liabilities
59.9M
↑ 10.83%
Q4 FY22Q/Q Change
Total Assets
583.4M
↑ 9.41%
Total Liabilities
81.6M
↑ 36.23%
Q1 FY23Q/Q Change
Total Assets
617.8M
↑ 5.9%
Total Liabilities
88.3M
↑ 8.18%
Q2 FY23Q/Q Change
Total Assets
524.6M
↓ 15.09%
Total Liabilities
103.0M
↑ 16.71%
Q3 FY23Q/Q Change
Total Assets
594.0M
↑ 13.23%
Total Liabilities
132.3M
↑ 28.47%
Q4 FY23Q/Q Change
Total Assets
621.5M
↑ 4.63%
Total Liabilities
114.8M
↓ 13.25%
FY18Y/Y Change
Operating Cash Flow
115.7M
↑ 89.82%
Investing Cash Flow
-90.8M
↑ 23.57%
Financing Cash Flow
-14.3M
↑ 80.25%
FY19Y/Y Change
Operating Cash Flow
136.1M
↑ 17.68%
Investing Cash Flow
-117.8M
↑ 29.81%
Financing Cash Flow
-28.6M
↑ 99.83%
FY20Y/Y Change
Operating Cash Flow
152.0M
↑ 11.65%
Investing Cash Flow
-119.3M
↑ 1.22%
Financing Cash Flow
12.2M
↓ 142.64%
FY21Y/Y Change
Operating Cash Flow
167.9M
↑ 10.48%
Investing Cash Flow
136.1M
↓ 214.14%
Financing Cash Flow
-302.6M
↓ 2577.41%
FY22Y/Y Change
Operating Cash Flow
120.3M
↓ 28.33%
Investing Cash Flow
-114.3M
↓ 183.99%
Financing Cash Flow
-17.3M
↓ 94.29%
Q3 FY22Q/Q Change
Operating Cash Flow
33.6M
↑ 86.52%
Investing Cash Flow
-4.8M
↓ 88.54%
Financing Cash Flow
-14.0M
↑ 406.57%
Q4 FY22Q/Q Change
Operating Cash Flow
33.4M
↓ 0.77%
Investing Cash Flow
-17.2M
↑ 259.94%
Financing Cash Flow
-61.0K
↓ 99.56%
Q1 FY23Q/Q Change
Operating Cash Flow
26.0M
↓ 22.26%
Investing Cash Flow
207.5M
↓ 1303.38%
Financing Cash Flow
181.0K
↓ 396.72%
Q2 FY23Q/Q Change
Operating Cash Flow
42.3M
↑ 62.91%
Investing Cash Flow
-24.1M
↓ 111.61%
Financing Cash Flow
-145.8M
↓ 80627.07%
Q3 FY23Q/Q Change
Operating Cash Flow
52.9M
↑ 25.12%
Investing Cash Flow
-109.6M
↑ 354.7%
Financing Cash Flow
-3.9M
↓ 97.31%

Technicals Summary

Sell

Neutral

Buy

Corcept Therapeutics Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Corcept Therapeutics Inc
Corcept Therapeutics Inc
-4.77%
-17.59%
3.07%
1.69%
96.52%
Moderna, Inc.
Moderna, Inc.
-0.38%
12.96%
-27.86%
-39.2%
336.75%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.39%
6.51%
9.62%
78.78%
144.38%
Novo Nordisk A/s
Novo Nordisk A/s
-6.76%
22.49%
44.85%
243.36%
401.52%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.41%
6.25%
21.24%
81.12%
121.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Corcept Therapeutics Inc
Corcept Therapeutics Inc
25.01
25.01
0.61
1.09
0.21
0.11
NA
4.9
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.75
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.04
26.04
1.46
45.03
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.46
46.46
2.4
3.31
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.57
28.57
0.53
16.62
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Corcept Therapeutics Inc
Corcept Therapeutics Inc
Buy
$2.4B
96.52%
25.01
22.0%
Moderna, Inc.
Moderna, Inc.
Buy
$40.3B
336.75%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.3B
144.38%
26.04
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$564.6B
401.52%
46.46
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$102.5B
121.07%
28.57
36.68%

Institutional Holdings

  • BlackRock Inc

    15.85%

  • Vanguard Group Inc

    9.21%

  • Ingalls & Snyder LLC

    8.07%

  • Renaissance Technologies Corp

    6.50%

  • Parallel Advisors, LLC

    3.64%

  • State Street Corporation

    3.27%

Company Information

leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis

Organization
Corcept Therapeutics Inc
Employees
352
CEO
Dr. Joseph K. Belanoff M.D.
Industry
Health Technology

Discover More

FAQs